Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

A Novel Hemostatic Monitoring System Convertible to FVIII Activity Based on Non-Activated ROTEM (NATEM) for Hemophilia a Patients during Emicizumab Prophylaxis

Koji Yada, MD PhD, Keiji Nogami, MD PhD, Ryu Kasai, MSc, Midori Shima, MD PhD

Blood (2018) 132 (Supplement 1): 3782.

https://doi.org/10.1182/blood-2018-99-117877

Published: 2018

Journal Articles

A Novel Mechanism of Factor VIIa/Tissue Factor (TF)-Catalyzed Activation and Inactivation of B-Domain-Deleted Factor VIII in the Early Initiation Phases of Coagulation

Yuto Nakajima, MD, Koji Yada, MD PhD, Keiji Nogami, MDPhD, Midori Shima, MD PhD

Blood (2018) 132 (Supplement 1): 1162.

https://doi.org/10.1182/blood-2018-99-115645

Published: 2018

Journal Articles

Increasing of Ternary Complex Formation By Predominant Accumulation of Factor (F)X Accompanied By Increase of Fixa Contributes to Enhancement of Clotting Function By Apcc in Combination with Emicizumab

Koji Yada, MD PhD, Keiji Nogami, MDPhD, Tomoko Matsumoto, PhD, Takehisa Kitazawa, DVM, Midori Shima, MDPhD

Blood (2017) 130 (Supplement 1): 3658.

https://doi.org/10.1182/blood.V130.Suppl_1.3658.3658

Published: 2017

Journal Articles

A New Classification of Mild/Moderate Hemophilia Α Based on a Multi-Dimensional FVIII(a) Functions Evaluated By a Plasma-Based Factor Xa Generation

Koji Yada, MD PhD, Keiji Nogami, MD PhD, Arisa Takenaka, Takeshi Kawamura, Midori Shima, MD PhD

Blood (2016) 128 (22): 1392.

https://doi.org/10.1182/blood.V128.22.1392.1392

Published: 2016

Journal Articles

A Factor VIII with Site-Specific Pegylation Attenuates the Binding with Inhibitors Results in the Retention of Hemostatic Effect

Koji Yada, MDPhD, Keiji Nogami, MDPhD, Chandra Patel, Derek Sim, Katalin Kauser, MD PhD, Midori Shima, MD PhD

Blood (2015) 126 (23): 1076.

https://doi.org/10.1182/blood.V126.23.1076.1076

Published: 2015

Journal Articles

ACE910 Facilitates Its Hemostatic Effect with the Lower Concentration of Factor X Than That Required for Factor VIIa-Driven Coagulation

Koji Yada, MD PhD, Keiji Nogami, MD PhD, Takehisa Kitazawa, DVM, Kunihiro Hattori, PhD, Midori Shima, MD PhD

Blood (2015) 126 (23): 1077.

https://doi.org/10.1182/blood.V126.23.1077.1077

Published: 2015

Journal Articles

Enhanced Global Hemostatic Potentials with a Bispecific Antibody to Factors IXa and X (ACE910) in the Whole Blood By Rotation Thromboelastometry (ROTEM)

Koji Yada, MDPhD, Keiji Nogami, MD PhD, Yasuaki Shida, MD PhD, Masahiro Takeyama, MD PhD, Ryu Kasai, MSc, Midori Shima, MD PhD

Blood (2015) 126 (23): 3503.

https://doi.org/10.1182/blood.V126.23.3503.3503

Published: 2015

Journal Articles

The Hemostatic Impairment in Mild Hemophilia Α Possessing Arg593Cys Mutation Is Caused By the Attenuated Binding to Phospholipid

Nao Kamiya, Koji Yada, MD PhD, Midori Shima, MD PhD, Keiji Nogami, MD PhD

Blood (2014) 124 (21): 2810.

https://doi.org/10.1182/blood.V124.21.2810.2810

Published: 2014

Journal Articles

Activated Protein C-Catalyzed Factor Va Inactivation Predominantly Contributes to the Downregulation of Coagulation Rather Than Factor VIIIa Inactivation

Koji Yada, MD PhD, Keiji Nogami, MD PhD, Tomoko Matsumoto, PhD, Takehisa Kitazawa, DVM, Kunihiro Hattori, PhD, Midori Shima, MD PhD

Blood (2014) 124 (21): 4222.

https://doi.org/10.1182/blood.V124.21.4222.4222

Published: 2014

Journal Articles

Identification Of The Thrombin-Binding Site On Factor VIII Regulating Arg 372 Cleavage In The Factor VIII Heavy Chain

Hiroaki Minami, MD, Keiji Nogami, MD, PhD, Koji Yada, MD, PhD, Midori Shima, MD, PhD

Blood (2013) 122 (21): 3570.

https://doi.org/10.1182/blood.V122.21.3570.3570

Published: 2013

Journal Articles

Reduced Affinity To VWF Induced By a Novel Mutation At Pro1809Leu (factor VIII-Tenri) Is The Cause Of Mild Hemophilia A Developing Anti-Factor VIII Inhibitor

Koji Yada, MD, PhD, Keiji Nogami, MD, PhD, Masahiro Takeyama, MD, PhD, Hiroaki Minami, MD, Philip J. Fay, PhD, Midori Shima, MD, PhD

Blood (2013) 122 (21): 2343.

https://doi.org/10.1182/blood.V122.21.2343.2343

Published: 2013

Journal Articles

An Optimal Monitoring On Bypassing Therapy for Hemophilia A Patients with Inhibitor Using aPTT-Based Clot Waveform Analysis with the Presence of Minimal TF

Junka Haku, MD, Kenichi Ogiwara, MD, PhD, Tomoko Matsumoto, PhD, Koji Yada, MD, Midori Shima, MD, PhD, Keiji Nogami, MD, PhD

Blood (2012) 120 (21): 3382.

https://doi.org/10.1182/blood.V120.21.3382.3382

Published: 2012

Journal Articles

A Coagulation Mechanism for the Mild Bleeding Tendency in a Patient with Severe Hemophilia A Possessing an Arg1781His Mutation.

Koji Yada, MD, Keiji Nogami, MD, PhD, Kenichi Ogiwara, MD, PhD, Hironao Wakabayashi, MD, PhD, Philip J. Fay, PhD, Midori Shima, MD, PhD

Blood (2012) 120 (21): 2213.

https://doi.org/10.1182/blood.V120.21.2213.2213

Published: 2012

Journal Articles

The Characteristics and Mechanism(s) of Anti-Factor VIII Antibody Developed in Mild Hemophilia A Associated with a Novel Mutation Pro1809Leu.

Koji Yada, MD, Keiji Nogami, MD, PhD, Kenichi Ogiwara, MD, PhD, Midori Shima, MD, PhD

Blood (2012) 120 (21): 2215.

https://doi.org/10.1182/blood.V120.21.2215.2215

Published: 2012

Journal Articles

Pharmacokinetics of Continuous Infusion Therapy of Factor VIII Concentrates in Hemophilia A Patients with Inhibitors,

Katsumi Nishiya, MD, PhD, Ichiro Tanaka, MD, PhD, Keiji Nogami, MD, PhD, Kenichi Ogiwara, MD, PhD, Koji Yada, MD, Tomoko Matsumoto, Midori Shima, MD, PhD

Blood (2011) 118 (21): 3320.

https://doi.org/10.1182/blood.V118.21.3320.3320

Published: 2011

Journal Articles

Mechanism of the Potent Activated Protein C Resistance of Novel Factor V Mutation with W1920R (FV Nara) Relative to R506Q (FV Leiden)

Kenichi Ogiwara, MD, PhD, Keiko Shinozawa, PhD, Keiji Nogami, MD, PhD, Tomoko Matsumoto, Katsumi Nishiya, MD, PhD, Nobuyuki Tsujii, MD, Koji Yada, MD, Katsuyuki Fukutake, MD, PhD, Midori Shima, MD, PhD

Blood (2011) 118 (21): 537.

https://doi.org/10.1182/blood.V118.21.537.537

Published: 2011

Journal Articles

A novel mechanism of Enhancing the Haemostatic Effect in the Combination with Recombinant Factor VIII and Activated Prothrombin Complex Concentrate(APCC) in Hemophilia A Patients with Inhibitor

Koji Yada, MD, Keiji Nogami, MD, PhD, Kenichi Ogiwara, MD, PhD, Midori Shima, MD, PhD

Blood (2011) 118 (21): 1178.

https://doi.org/10.1182/blood.V118.21.1178.1178

Published: 2011

Journal Articles

Effects of Anti-FVIII Inhibitors On Factor VIIa/Tissue Factor-Catalyzed Activation and Inactivation of Factor VIII.

Koji Yada, Keiji Nogami, Kenichi Ogiwara, Katsumi Nishiya, Masahiro Takeyama, Midori Shim

Blood (2009) 114 (22): 3169.

https://doi.org/10.1182/blood.V114.22.3169.3169

Published: 2009

NARROW

A Novel Hemostatic Monitoring System Convertible to FVIII Activity Based on Non-Activated ROTEM (NATEM) for Hemophilia a Patients during Emicizumab Prophylaxis

A Novel Mechanism of Factor VIIa/Tissue Factor (TF)-Catalyzed Activation and Inactivation of B-Domain-Deleted Factor VIII in the Early Initiation Phases of Coagulation

Increasing of Ternary Complex Formation By Predominant Accumulation of Factor (F)X Accompanied By Increase of Fixa Contributes to Enhancement of Clotting Function By Apcc in Combination with Emicizumab

A New Classification of Mild/Moderate Hemophilia Α Based on a Multi-Dimensional FVIII(a) Functions Evaluated By a Plasma-Based Factor Xa Generation

A Factor VIII with Site-Specific Pegylation Attenuates the Binding with Inhibitors Results in the Retention of Hemostatic Effect

ACE910 Facilitates Its Hemostatic Effect with the Lower Concentration of Factor X Than That Required for Factor VIIa-Driven Coagulation

Enhanced Global Hemostatic Potentials with a Bispecific Antibody to Factors IXa and X (ACE910) in the Whole Blood By Rotation Thromboelastometry (ROTEM)

The Hemostatic Impairment in Mild Hemophilia Α Possessing Arg593Cys Mutation Is Caused By the Attenuated Binding to Phospholipid

Activated Protein C-Catalyzed Factor Va Inactivation Predominantly Contributes to the Downregulation of Coagulation Rather Than Factor VIIIa Inactivation

Identification Of The Thrombin-Binding Site On Factor VIII Regulating Arg 372 Cleavage In The Factor VIII Heavy Chain

Reduced Affinity To VWF Induced By a Novel Mutation At Pro1809Leu (factor VIII-Tenri) Is The Cause Of Mild Hemophilia A Developing Anti-Factor VIII Inhibitor

An Optimal Monitoring On Bypassing Therapy for Hemophilia A Patients with Inhibitor Using aPTT-Based Clot Waveform Analysis with the Presence of Minimal TF

A Coagulation Mechanism for the Mild Bleeding Tendency in a Patient with Severe Hemophilia A Possessing an Arg1781His Mutation.

The Characteristics and Mechanism(s) of Anti-Factor VIII Antibody Developed in Mild Hemophilia A Associated with a Novel Mutation Pro1809Leu.

Pharmacokinetics of Continuous Infusion Therapy of Factor VIII Concentrates in Hemophilia A Patients with Inhibitors,

Mechanism of the Potent Activated Protein C Resistance of Novel Factor V Mutation with W1920R (FV Nara) Relative to R506Q (FV Leiden)

A novel mechanism of Enhancing the Haemostatic Effect in the Combination with Recombinant Factor VIII and Activated Prothrombin Complex Concentrate(APCC) in Hemophilia A Patients with Inhibitor

Effects of Anti-FVIII Inhibitors On Factor VIIa/Tissue Factor-Catalyzed Activation and Inactivation of Factor VIII.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only